Effect of Circulating lncRNAs on Type 2 Diabetic Peripheral Neuropathy

  • STATUS
    Recruiting
  • End date
    Dec 31, 2022
  • participants needed
    300
  • sponsor
    Jinshan Hospital Fudan University
Updated on 27 January 2021

Summary

This project intends to use high-throughput sequencing, molecular biology and bioinformatics technology to clarify the role of target lncrnas in the inflammatory response of DPN, to explore the correlation between target lncrnas and DPN pathogenesis, and to clarify the feasibility of target lncrnas as a marker of DPN cycle.

Description

  1. Screening lncrnas that regulate DPN inflammatory response and bind to miR-146a

Experimental grouping The experiment was divided into T2DM group and DPN group. T2DM group was simple type 2 diabetes, without complications and other basic diseases; DPN group was simple T2DM patients with DPN. The diagnostic criteria for T2DM patients were in accordance with the Chinese guidelines for the prevention and treatment of type 2 diabetes (2017 Edition). The screening criteria for T2DM patients with DPN are as follows: 1. Clear history of type 2 diabetes mellitus. 2. Neuropathy at or after the diagnosis of diabetes. 3. The clinical symptoms and signs were consistent with those of DPN. Clinical symptoms include: numbness or sensation; tingling or tingling; pain; abnormal sensitivity or tenderness after touching. 4. Examination: A. abnormal temperature sense; B. 10 g nylon thread examination, foot sensation decreased or disappeared; C. abnormal vibration sense; D. ankle reflex disappeared; e. two or more items of nerve conduction velocity were slowed down (electromyography or sensory threshold measurement). 5. Nerve injury caused by other diseases or drugs was excluded. Two of the above five items were abnormal, or clinical symptoms + 1 item were abnormal. Under the condition of full informed consent, 3ml plasma samples were collected from T2DM group and DPN group, 4 copies in each group, and stored in refrigerator at - 80 . Screening of lncrnas and mRNAs differentially expressed in two groups of samples by gene sequencing.

Total RNA was extracted from tissue samples. The concentration and purity of RNA were detected by Nanodrop2000. The integrity of RNA was detected by agarose gel electrophoresis, and RIN value was determined by Agilent2100. The total RNA of a single library was 2 UG, the concentration was more than 100 ng / L, od260 / 280 was between 1.8 ~ 2.2, and rRNA was removed. Using metal ions, the mRNA was randomly broken into small fragments of about 200 bp. Under the action of reverse transcriptase, a single strand of cDNA was synthesized by using random primers and using mRNA as template.

The second strand of cDNA was synthesized by substituting dUTP for dTTP. The structure of the double stranded cDNA is a sticky end. The end repair mix is added to make up the flat end, and then an a base is added at the 3 'end to connect the Y-shaped junction. The second strand of cDNA was digested by ung enzyme so that only the first strand of cDNA was contained in the library. Then the Illumina sequencer platform was used for sequencing to obtain the original sequencing data. The differentially expressed lncrnas and mRNAs were obtained by quality control and sequence alignment. The lncrnas with difference multiple 2 were obtained, and the lncrnas co expressed with inflammatory factors were determined by co expression analysis. Different lncnras were retrieved from mircode and Starbase databases to obtain lncnras combined with miR-146a.

2. In vitro validation of candidate lncnras:

high concentration glucose (200mmol / L) induced injury of Schwann cells; detection of the expression of candidate lncnras and miR-146a in high glucose induced Schwann cells to obtain lncnras with high expression; double luciferase reporter gene experiment to verify the combination of candidate lncnras and miR-146a, and obtain candidate lncnras binding to miR-146a; construction Methods: lncnras silencing vector was used to transfer candidate lncnras into high glucose induced Schwann cells; Western blot and liquid chip were used to detect the levels of inflammatory factors (TNF

  • , IL-1 , IL-6 and IL-10) in Schwann cells; and correlation analysis was used to determine the lncrnas positively correlated with inflammatory factors. 3. Large plasma samples were used to verify the correlation between candidate lncrnas and miR-146a and inflammatory factors.
  • the experimental grouping was the same as before; with full informed consent, 50 plasma samples were collected from T2DM patients and T2DM patients with DPN, each 3ml each. candidate lncrnas and miR-146a primers were designed and QRT PCR was used to detect the candidate lncrnas and miR-146a The levels of inflammatory factors (TNF - , IL-1 , IL-6 and IL-10) in the plasma of the two groups were detected by liquid chip technology; lncrnas negatively correlated with miR-146a and positively correlated with the expression of inflammatory factors were determined by correlation analysis. 4. Statistical treatment: SPSS 23.0 software was used for statistical analysis. The measurement data are expressed as mean SD One way ANOVA or nonparametric test was used to analyze the distribution and grouping characteristics. Pearson correlation analysis was used to analyze the correlation of measurement data. With P < 0.05, the difference was statistically significant. 5. Technical route this study is mainly divided into three parts. Firstly, lncrnas that regulate DPN inflammatory response and bind with miR-146a are screened; on this basis, candidate lncnras are obtained by in vitro validation; finally, lncnras with molecular marker function are verified on large sample plasma samples. 6. Technical difficulties In this study, we used gene sequencing technology to detect the differential expression of lncrnas and mRNAs in plasma of T2DM patients and DPN patients, combined with bioinformatics technology to screen lncrnas related to inflammation and bind to miR-146a. Objective to screen for miR-146a binding proteins associated with inflammation Lncrnas are the technical difficulties in this study.

Details
Condition Diabetic Peripheral Neuropathy
Treatment lncRNA detection
Clinical Study IdentifierNCT04638556
SponsorJinshan Hospital Fudan University
Last Modified on27 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 80 yrs?
Gender: Male or Female
Do you have any of these conditions: Do you have Diabetic Peripheral Neuropathy??
Patients who were diagnosed with type 2 diabetes in accordance with the
Chinese guidelines for the prevention and treatment of type 2 diabetes (2017
Edition) Neuropathy at or after the diagnosis of diabetes Clinical symptoms
include: numbness or sensation, tingling or tingling, pain, abnormal
sensitivity or tenderness after touching
Examination item include
abnormal temperature sense
10 g nylon thread examination, foot sensation decreased or disappeared
abnormal vibration sense
ankle reflex disappeared
two or more items of nerve conduction velocity were slowed down (electromyography or sensory threshold measurement) Patients with two of the above five items were abnormal, or patients with clinical symptoms plus 1 item

Exclusion Criteria

Nerve injury caused by other diseases or drugs Patients with T1DM or other
endocrine system diseases, acute complications of diabetes, such as diabetic
ketoacidosis and hypertonic non ketotic coma, cardiovascular and
cerebrovascular diseases, nonalcoholic fatty liver disease, liver and kidney
failure, inflammatory diseases, active infection, cancer, pregnancy or
lactation Patients with a systolic blood pressure(SBP) 160 mmHg or 100 mmHg or
a diastolic blood pressure(DBP) 95 mmHg or 60 mmHg In addition to the above
items, patients who are deemed inappropriate by clinical trial researchers
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note